NCT00795925View on ClinicalTrials.gov

Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

December 31, 2005

Conditions
Overactive Bladder
Interventions
DRUG

propiverine hydrochloride

"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."

All Listed Sponsors
lead

APOGEPHA Arzneimittel GmbH

INDUSTRY

NCT00795925 - Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder | Biotech Hunter | Biotech Hunter